659 diabetic patients aged >18 years with inadequate glycemic control with metformin monotherapy (366 on FDC and 293 on free-dose therapy)
5/1000; once daily: Metformin + TZD:
(August 26, 2022) A three-drug medication known as a “polypill,” developed by the Spanish National Center for Cardiovascular Research (CNIC) and Ferrer, is effective in
Abstract
Viera’s article on the polypill focused exclusively on cardiovascular benefits
The main question it aims to answer is: That the GMRx-4 IR polypill, compared to metformin, will improve glucose lowering in those with recently diagnosed Type 2